Abstract
Objective: This retrospective, case–control study was executed to assess the effects of digoxin (DGX) use approaches [continuous use of DGX (cDGX) vs. intermittent use of DGX (iDGX)] on the long-term prognosis in rheumatic heart disease (RHD) patients with heart failure (HF).Methods: A total of 642 RHD patients were enrolled to this study after propensity matching. The associations of DGX application approaches with the risks of all-cause mortality, cardiovascular death (CVD), HF re-hospitalization (1-, 3-, and 5-year), and new-onset atrial fibrillation (AF) were analyzed by multivariate Cox proportional hazards or binary logistic regression models, respectively.Results: cDGX was associated with increased risks of all-cause mortality (adjusted HR = 1.84, 95% CI: 1.27–2.65, P = 0.001) and CVD (adjusted HR = 2.23, 95% CI: 1.29–3.83, P = 0.004) in RHD patients with HF compared to iDGX. With exception of 1-year HF re-hospitalization risk, cDGX was associated with increased HF re-hospitalization risk of 3-year (adjusted OR = 1.53, 95% CI: 1.03–2.29, P = 0.037) and 5-year (adjusted OR = 1.61, 95% CI: 1.05–2.50, P = 0.031) as well as new-onset AF (adjusted OR = 2.06, 95% CI: 1.09–3.90, P = 0.027).Conclusion: cDGX was significantly associated with increased risks of all-cause mortality, CVD, medium-/long-term HF re-hospitalization, and new-onset AF in RHD patients with HF.
Highlights
Cheng Liu 1,2*†, Yanxian Lai 1†, Tianwang Guan 2, Qingchun Zeng 3, Jingxian Pei 4, Shenghui Zhang 1, Daihong Wu 2 and Deping Wu 5
Results: continuous use of DGX (cDGX) was associated with increased risks of all-cause mortality
hazard ratio (HR) = 1.84, 95% confidence interval (CI): 1.27–2.65, P = 0.001) and cardiovascular death (CVD) in rheumatic heart disease (RHD) patients with heart failure (HF) compared to intermittent use of DGX (iDGX)
Summary
Cheng Liu 1,2*† , Yanxian Lai 1† , Tianwang Guan 2 , Qingchun Zeng 3 , Jingxian Pei 4 , Shenghui Zhang 1 , Daihong Wu 2 and Deping Wu 5.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.